相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
Naru Kondo et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Carbohydrate Antigen 19-9 Change During Chemotherapy for Advanced Pancreatic Adenocarcinoma
Michele Reni et al.
CANCER (2009)
Margin Clearance and Outcome in Resected Pancreatic Cancer
David K. Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Young Choon Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival After Pancreatectomy of Curative Intent
Jonathan M. Hernandez et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?
O. Turrini et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Joshua G. Barton et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy With 5-FU-Based Concurrent Chemotherapy for Resectable Pancreatic Cancer
Timothy J. Kinsella et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Influence of resection margins and treatment on survival in patients with pancreatic cancer - Meta-analysis of randomized controlled trials
Giovanni Butturini et al.
ARCHIVES OF SURGERY (2008)
Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration
S. L. Ong et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Adam C. Berger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess et al.
LANCET ONCOLOGY (2008)
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
Derrick Wong et al.
PANCREAS (2008)
The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer
Chang Moo Kang et al.
JOURNAL OF SURGICAL RESEARCH (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
K. S. Goonetilleke et al.
EJSO (2007)
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
Stefan Boeck et al.
ONCOLOGY (2006)
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
NR Maisey et al.
BRITISH JOURNAL OF CANCER (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Utility of tumor markers in determining resectability of pancreatic cancer
MG Schlieman et al.
ARCHIVES OF SURGERY (2003)
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
DV Mann et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2000)
分享论文
